When did MONOPAR THERAPEUTICS INC (MNPR) report earnings last quarter?
MONOPAR THERAPEUTICS INC (MNPR) last reported earnings on 11/13/2025.
NASDAQ:MNPR • US61023L2079
Past quarterly earnings results for MONOPAR THERAPEUTICS INC (MNPR), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.48 | -0.44 | -9.44% | -29.73% | - | - | ||
| Q2 2025 | -0.35 | -0.48 | 27.30% | 30.00% | - | - | ||
| Q1 2025 | -0.38 | -0.69 | 45.21% | 24.00% | - | - | ||
| Q4 2024 | -2.75 | -0.43 | -541.92% | -358.33% | - | - | ||
| Q3 2024 | -0.37 | -0.49 | 23.90% | 47.14% | - | - | ||
| Q2 2024 | -0.50 | -0.48 | -5.05% | 37.50% | - | - | ||
| Q1 2024 | -0.50 | -0.61 | 18.30% | 47.37% | - | - | ||
| Q4 2023 | -0.60 | -0.79 | 24.10% | 47.83% | - | - | ||
| Q3 2023 | -0.70 | -0.87 | 19.26% | 26.32% | - | - | ||
| Q2 2023 | -0.80 | -0.94 | 14.75% | 27.27% | - | - | ||
| Q1 2023 | -0.95 | -1.13 | 16.09% | - | - | - | ||
| Q4 2022 | -1.15 | -1.05 | -10.00% | -9.52% | - | - | ||
| Q3 2022 | -0.95 | -1.11 | 14.36% | 5.00% | - | - | ||
| Q2 2022 | -1.10 | -1.05 | -4.36% | -29.41% | - | - | ||
| Q1 2022 | -0.95 | -1.13 | 16.28% | -18.75% | - | - | ||
| Q4 2021 | -1.05 | -0.97 | -8.36% | -5.00% | - | - | ||
| Q3 2021 | -1.00 | -1.08 | 7.73% | -33.33% | - | - | ||
| Q2 2021 | -0.85 | -0.98 | 13.42% | -21.43% | - | - | ||
| Q1 2021 | -0.80 | -0.95 | 15.97% | -60.00% | - | - | ||
| Q4 2020 | -1.00 | -0.96 | -4.58% | - | - | - | ||
| Q3 2020 | -0.75 | -0.78 | 4.09% | - | - | - | ||
| Q2 2020 | -0.70 | -0.46 | -52.51% | - | - | - | ||
| Q1 2020 | -0.50 | -0.56 | 10.87% | - | - | - |
Notes
MONOPAR THERAPEUTICS INC (MNPR) last reported earnings on 11/13/2025.
MONOPAR THERAPEUTICS INC (MNPR) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, MONOPAR THERAPEUTICS INC (MNPR) has beaten EPS estimates in 2 out of 4 releases.